Therapix Biosciences Ltd.
TRPX
TRPX was delisted on the 1st of July, 2020.
4 hedge funds and large institutions have $20K invested in Therapix Biosciences Ltd. in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
136% more capital invested
Capital invested by funds: $8.47K → $20K (+$11.5K)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
+$24.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.54K |
| 2 |
APA
American Portfolios Advisors
Holbrook,
New York
|
-$474 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
1
A.R.T. Advisors
New York
| $15K | +$24.9K | +13,504 | New |
|
|
2
Morgan Stanley
New York
| $2K | -$1.54K | -837 | -36% |
|
|
3
UBS Group
Zurich,
Switzerland
| $2K | +$2.87K | +1,559 | +471% |
|
4
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
APA
5
American Portfolios Advisors
Holbrook,
New York
| – | -$474 | -200 | Closed |
|
TRPX Hedge Fund Activity: Q4 2019 in Review
4 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Therapix Biosciences Ltd. (TRPX) for Q4 2019, worth a combined $20K — up 136% from $8.47K a quarter earlier.
Fund positioning in TRPX was balanced in Q4 2019: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $24.9K. The largest seller was Morgan Stanley, cutting an estimated $1.54K.
- 4 institutional investors held Therapix Biosciences Ltd. (TRPX) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $20K of Therapix Biosciences Ltd. stock for Q4 2019, up 136% quarter-over-quarter.
- 1 fund opened new Therapix Biosciences Ltd. positions in Q4 2019 and 1 closed out, a net change of 0 holders.
- The largest Therapix Biosciences Ltd. buyer in Q4 2019 was A.R.T. Advisors, an estimated $24.9K added.
- The largest Therapix Biosciences Ltd. seller in Q4 2019 was Morgan Stanley, an estimated $1.54K sold.
Based on aggregated 13F filings for Q4 2019.